Additive Effect of Pronase on the Eradication Rate of First-Line Therapy for Helicobacter pylori Infection
0
조회
0
다운로드
9
인용
0
참고문헌
키워드
초록
Background/Aims: Helicobacter pylori colonizes on the apical surface of gastric surface mucosal cells and the surface mucous gel layer. Pronase is a premedication enzyme for endoscopy that can disrupt the gastric mucus layer. We evaluated the additive effects of pronase combined with standard triple therapy for H. pylori eradication. Methods: This prospective, single-blinded, randomized, controlled study was conducted between June and October 2012. A total of 116 patients with H. pylori infection were enrolled in the study (n=112 patients, excluding four patients who failed to meet the inclusion criteria) and were assigned to receive either the standard triple therapy, which consists of a proton pump inhibitor with amoxicillin and clarithromycin twice a day for 7 days (PAC), or pronase (20,000 tyrosine units) combined with the standard triple therapy twice a day for 7 days (PACE). Results: In the intention-to-treat analysis, the eradication rates of PAC versus PACE were 76.4% versus 56.1% (p=0.029). In the per-protocol analysis, the eradication rates were 87.5% versus 68.1% (p=0.027). There were no significant differences concerning adverse reactions between the two groups. Conclusions: According to the interim analysis of the trial, pronase does not have an additive effect on the eradication of H. pylori infection (ClinicalTrial.gov: NCT01645761).
Abstract
Background/Aims: Helicobacter pylori colonizes on the apical surface of gastric surface mucosal cells and the surface mucous gel layer. Pronase is a premedication enzyme for endoscopy that can disrupt the gastric mucus layer. We evaluated the additive effects of pronase combined with standard triple therapy for H. pylori eradication. Methods: This prospective, single-blinded, randomized, controlled study was conducted between June and October 2012. A total of 116 patients with H. pylori infection were enrolled in the study (n=112 patients, excluding four patients who failed to meet the inclusion criteria) and were assigned to receive either the standard triple therapy, which consists of a proton pump inhibitor with amoxicillin and clarithromycin twice a day for 7 days (PAC), or pronase (20,000 tyrosine units) combined with the standard triple therapy twice a day for 7 days (PACE). Results: In the intention-to-treat analysis, the eradication rates of PAC versus PACE were 76.4% versus 56.1% (p=0.029). In the per-protocol analysis, the eradication rates were 87.5% versus 68.1% (p=0.027). There were no significant differences concerning adverse reactions between the two groups. Conclusions: According to the interim analysis of the trial, pronase does not have an additive effect on the eradication of H. pylori infection (ClinicalTrial.gov: NCT01645761).
참고문헌 (19)
- Graham DY, "A report card to grade Helicobacter pylori therapy", Helicobacter, 12, pp.275~278 (2007)
- Graham DY, "New concepts of resistance in the treatment of Helicobacter pylori infections", Nat Clin Pract Gastroenterol Hepatol, 5, pp.321~331 (2008)
- Graham DY, "Helicobacter pylori treatment in the era of increasing antibiotic resistance", Gut, 59, pp.1143~1153 (2010)
- Fujii T, "Effectiveness of premedication with pronase for improving visibility during gastroendoscopy: a randomized controlled trial", Gastrointest Endosc, 47, pp.382~387 (1998)
- Koga M, "On the application of enzymatic mucinolysis in X-ray diagnosis of the stomach", Nihon Igaku Hoshasen Gakkai Zasshi, 24, pp.1011~1031 (1964)
- Ida K, "Clinical evaluation of premedication with KPD (pronase) in gastroendoscopy: placebo-controlled double blind study in dye scattering endoscopy", Clin Rep, 25, pp.1793~1804 (1991)
- Gotoh A, "Additive effect of pronase on the efficacy of eradication therapy against Helicobacter pylori", Helicobacter, 7, pp.183~191 (2002)
- Hashimoto Y, "Action of proteolytic enzymes on purified bovine submaxillary mucin", Ann N Y Acad Sci, 106, pp.233~246 (1963)
- Taniguchi Y, "Cytoprotection by 16,16-dimethylprostaglandin E2. Role of gastric juice and mucus gel layer", J Clin Gastroenterol, 14(1), pp.S52~S58 (1992)
- Hazell SL, "Campylobacter pyloridis and gastritis: association with intercellular spaces and adaptation to an environment of mucus as important factors in colonization of the gastric epithelium", J Infect Dis, 153, pp.658~663 (1986)
- Shimizu T, "Helicobacter pylori and the surface mucous gel layer of the human stomach", Helicobacter, 1, pp.207~218 (1996)
- Chung JW, "The trends of one-week first-line and second-line eradication therapy for Helicobacter pylori infection in Korea", Hepatogastroenterology, 58, pp.246~250 (2011)
- Kimura K, "A 1-h topical therapy for the treatment of Helicobacter pylori infection", Am J Gastroenterol, 90, pp.60~63 (1995)
- amoxicillin in rat gastric tissue when administered with lansoprazole and clarithromycin, "J Antimicrob Chemother", 2001, 923~926
- Patel JK, "Formulation and evaluation of stomach-specific amoxicillin-loaded carbopol-934P mucoadhesive microspheres for anti-Helicobacter pylori therapy", J Microencapsul, 26, pp.365~376 (2009)
- Gyu Jin Lee, "Effectiveness of Premedication with Pronase for Visualization of the Mucosa during Endoscopy: A Randomized, Controlled Trial", Clinical Endoscopy, 45(2), pp.161~164 (2012), 대한소화기내시경학회
- Chang CC, "Premedication with pronase or N-acetylcysteine improves visibility during gastroendoscopy: an endoscopist-blinded, prospective, randomized study", World J Gastroenterol, 13, pp.444~447 (2007)
- Sherwood PV, "Impact of acid secretion, gastritis, and mucus thickness on gastric transfer of antibiotics in rats", Gut, 51, pp.490~495 (2002)
- Whitley E, "Statistics review 4: sample size calculations", Crit Care, 6, pp.335~341 (2002)